# ImmuPharma PLC Corporate Update

- Link: https://www.directorstalkinterviews.com/immupharma-plc-corporate-update/412773977
- Published: 2019-05-07T07:07:39+01:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON: IMM), the specialist drug discovery and development company
has today provided the following update on ongoing activities.

**Lupuzor™**

Lupuzor™ is the Company’s late stage asset for Lupus, a potential life threatening
auto-immune disease. Following the conclusion of the pivotal Phase III trial in 
2018, ImmuPharma continues to look at opportunities which the Board believes over
the longer term have the potential of bringing Lupuzor™ to market. As part of this
strategy, the Company confirms that it continues to engage with potential corporate
partners as well as consulting with regulatory advisors on potential pathways to
market. Whilst these activities continue the commencement of the Managed Access 
Program for Lupuzor™ will be postponed until the Company has further clarification
on these activities.

**Lupuzor™ Extension Study**

The Lupuzor™ open label extension study, from the original Phase III trial, with
a total of 62 eligible patients recruited throughout the US and Europe, remains 
on track to report results in Q2 2019.

**Merger of Elro Pharma and Ureka**

ImmuPharma’s subsidiaries Elro Pharma Sarl and Ureka Sarl, both based in France,
are focussing on unique technologies: the Nucant cancer programme (Elro) and the
peptide platform (Ureka).

As previously announced, the Company has been exploring its options to licence, 
divest or ‘spin-off’ the technologies of both of these subsidiaries to unlock their
future potential and enhance value to shareholders.

Following an internal review, the Company’s intention is to merge these two subsidiaries,
in order to create a stronger combined company with a platform technology together
with a drug candidate in clinical development, with a view to securing external 
investment either from private equity or through a public listing on a European 
stock exchange. This in turn would allow ImmuPharma PLC to focus on Lupuzor™ and
the overall P140 platform for different autoimmune indications

Further details will be announced in due course.

**Incanthera Limited**

Further to the announcement of 1 April 2019, all discussions with Incanthera on 
the Nucant cancer programme and broader collaboration discussions have now terminated.

**Final Results**

ImmuPharma plc will provide a further update on its operations and strategy in its
Final results for the year ended 31 December 2018, which are expected to be announced
by the end of this month.

Share on:
